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Background and Objectives: Marijuana (MJ) is a widely
used substance that has been shown to impair cognition in
laboratory settings. There is a growing number of medical MJ
dispensaries and state policies permitting the use of MJ in the
United States. This study is a naturalistic study that explores the
association of same day MJ use on self‐rated cognition in young
adult men and women.
Methods: Forty‐eight (n¼ 48) young adults (22 F; mean age¼ 22.3)
participated. After a baseline assessment, participants made daily
phone calls to study staff over the next 3 weeks. Cumulative minutes
of MJ use in the last 24‐hours were assessed. Demographic
information collected and self‐ratings of cognitive impairment were
assessed using six questions about areas of difﬁculty thinking each
day.
Results: There was a signiﬁcant relationship between greater number
of minutes of MJ use and higher levels of self‐rated cognitive
difﬁculties (b¼ .004; SE¼ .001; p< .006). There was no main effect
of gender (b¼ 1.0; SE¼ .81; p< .22). Planned evaluation of the
interaction between gender and minutes of MJ use was not signiﬁcant
statistically, suggesting a similar relationship between minutes of MJ
use and cognitive difﬁculties among women compared to men
(p< .54).
Conclusions and Scientiﬁc Signiﬁcance: There is an association
between current and heavy MJ use and self‐perceived cognitive
ability in both males and females. These ﬁndings reveal important
information regarding one consequence of MJ use that has real‐
world meaning to young adult smokers. (Am J Addict 2015;24:160–
165)
INTRODUCTION
Marijuana (MJ) is one of the most commonly used illicit
drugs and its use in young adults is once again on the rise.1
There are a growing number of medical MJ dispensaries and
state policies permitting the use of MJ in the United States.2
Given this increase in more lenient laws, there is a pressing
need to better understand the consequences of MJ use,
particularly those that are perceived by the user. This study
explores impact of MJ use on self‐rated cognition and whether
this differs between young adult men and women. Whether MJ
affects cognition in females andmales differently is an area that
is still poorly understood. Animal research has shown that
female rats are more sensitive to the effects of cannabinoids,
due in part to the lower number of CB1 recept or binding sites
in cerebral areas of females compared to males.3 In addition,
chronic exposure to THC has been shown to be associated with
different emotional responses in male and female rats.4,5 One
of the ﬁrst studies to show sex differences in MJ response in
cognitive tasks in humans was by Pope et al. (1997).6 In that
study, visuospatial memory tests were compared in males and
females who were heavy and light MJ smokers.
The study showed no signiﬁcant differences between
heavy and light smokers, but when females were analyzed
separately from males, heavy smoking females had more
difﬁculty remembering and made more errors than light
smoking females.6 Two recent reviews of the inﬂuence of sex
on the effect of MJ use7,8 highlight the inﬂuence of hormones
on the sensitivity of females to MJ exposure and the need for
the careful evaluation of potential differences in the effects of
MJ on cognition among females. However, no study has
systematically examined subjective differences in cognition
between males and females.
Studies have shown a clear connection between the acute
adverse effects of cannabis on cognition,9 but this changes
depending upon the frequency of use and length of
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abstinence.10 Recent studies conducted on the effects of MJ on
cognition in young adult users assess cognition well after the
use of MJ. A typical measure for “recent MJ use” is in the last
4 weeks.11–13 Another study on the effect of MJ use on
cognition in a young adult population asked that participants
refrain fromMJ use for at least 12 hours before testing so as not
to be high during the assessment.14 Therefore, consideration of
same day MJ use with self‐rated cognition would be an
important area of examination in studies of the effects of MJ on
neurocognition. In the current study, we investigated how
variations in MJ use inﬂuence self‐rated cognition when
assessed on a daily basis in a naturalistic setting. We
hypothesized that greater levels of MJ use would be associated
with lower self‐ratings of cognition, daily functioning, and that
females would report worse ratings than men.
METHODS
Participants
Participants (26 M; 22 F) between the ages of 18–30 were
recruited between March 2012 and March 2013 through on‐
line advertisements in Craig’s List and Facebook, looking for
“persons 18–29 who drink alcohol or smoke marijuana.”
Approximately half of the participants had at least a high
school education, were unemployed, or were students at the
time of the study (Table 1). At screening, young adults who
reported any MJ use in the past month were eligible. Because
we were interested in trying to isolate the effect of MJ on self‐
perceived cognition, our exclusion criteria were: (1) no past
month cocaine, opioid, benzodiazepine, or stimulant (methyl-
phenidate, amphetamine, methamphetamine) use or positive
urine toxicology for these substances prior to the baseline
interview; (2) no more than once a month binge drinking
(deﬁned as ﬁve or more drinks within a 2‐hour period for men;
four or more drinks within a 2‐hour period for women); (3)
night shift work; (4) self‐reported history of schizophrenia,
bipolar disorder; or currently medicated attention deﬁcit
hyperactive disorder; (5) lack of stable housing; (6) current
(past 2 weeks) suicidal ideation; and (7) past month use of sleep
medication or antidepressants. We also recruited through
Craig’s List and Facebook, an age‐matched group who
reported no MJ use in the last month to complete a continuum
of MJ use patterns. We included individuals with patterns of
MJ use that ranged from no‐use, non‐daily, and daily use who
provided reports of variability in daily functioning that could
be related to reported levels ofMJ use on use and non‐use days.
A total of 646 persons were screened by phone for
eligibility. Of these, 525 were ineligible due to recent binge
drinking or other alcohol‐related problems. An additional 44
were not eligible due to reporting one or more other exclusion
criteria. These included (numbers reported are not mutually
exclusive) use of other drugs (n¼ 22), mental disorder
diagnosis (schizophrenia, bipolar disorder, currentlymedicated
attention deﬁcit hyperactive disorder) (n¼ 23), currently being
treated for depression (n¼ 10), suicidality (n¼ 10), unstable
TABLE 1. Demographic characteristics of analysis sample
Variable Women (n¼ 22) % Men (n¼ 26) % p
Age (SD) 21.7 (2.68) 22.8 (3.19) .11
Age range 18–27 18–30
Education
12 8 44 10 55 .71
>12 14 50 14 50
Employment
Employed 10 46 12 55 .98
Unemployed 12 50 12 50
Student
No 12 44 15 56 .84
Yes 10 53 9 47
Tobacco use
No 19 51 18 49 .44
Yes 3 33 6 67
Marijuana use disorder
No 16 49 17 52
Yes 6 46 7 54 .99
Marijuana use
No use 5 56 4 44 .17
During study period
Non‐daily 10 44 13 57
Daily 7 44 9 56
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housing (n¼ 4), and no phone (n¼ 1). Of the eligible
participants, 6 could not be reached to schedule a baseline
appointment, 2 refused participation, and 20 did not come in
for their baseline appointment. Forty‐nine agreed to participate
in the study and were consented; and one person was not
included in analyses due to substantial missing data (n¼ 48).
Measures
All participants were administered a Structured clinical
interview for DSM‐IV—Patient version (SCID)15 at baseline
to assess for MJ dependence. Eligible participants were
provided with a daily diary created by the investigators, which
included questions about past 24‐hour substance use and self‐
rated cognitive impairment. Participants could provide a
maximum of 3 weeks of daily diary data.
MJ Use and Self‐Rated Cognition
Last 24‐hourMJ use was assessed at the daily calls.We used
minutes as a proxy of time spent smoking. The subject
estimated how many minutes they spent consuming/using/
smoking MJ and not the minutes they felt intoxicated. The
instruction given to subjects was: How many minutes do you
think you spent actually smoking marijuana?” The authors
chose to use minutes of MJ because it is very difﬁcult to
ascertain in the naturalistic setting exactly how much THC the
participant is ingesting. To clarify this measure further, we
made frequency of use in days (daily vs. non‐daily use) and
meeting a diagnosis of dependence as our secondary measures.
In addition, cumulative minutes of MJ use during four 6‐hour
blocks (midnight–6 am, 6 am–noon, noon–6 pm, 6 pm–mid-
night) were assessed. Self‐rating of cognitive impairment was
assessed using six questions from the cognition subscale of the
Medical Outcome Study Measure (cognitive function) short‐
form general health survey about areas of difﬁculty thinking
each day.16 Research staff asked, “Yesterday, how much of the
time did you: (1) have difﬁculty reasoning and solving
problems (eg, making plans, making decisions, learning new
things)?; (2) have difﬁculty doing activities involving
concentration and thinking?; (3) become confused and start
several actions at a time?; (4) forget, for example, things that
happened recently, where you put things, appointments?; (5)
have trouble keeping your attention on any activity for long?;
and (6) react slowly to things that were said or done? Six response
options (scored 0–5) ranged from none of the time to all of the
time. Responses were summed (possible range 0–30) and the
internal consistency reliability from the ﬁrst day of ratings for
this measure was good (Cronbach’s alpha¼ .85). The internal
consistency (Cronbach’s alpha) of the cognitive problems
instrument ranged from .84 to .92 across the evaluation days.
Procedures
Eligible individuals were asked to come in to Butler Hospital
for informed consent and a baseline interview. This study was
approved by the Institutional Review Boards of Butler Hospital
and theUniversity ofMichigan.At baseline, participants received
a 40‐minute face‐to‐face interview to assess demographics, and
MJ use. Participants also provided urine samples for toxicologi-
cal analysis to rule out recent drug use prior to this interview.
Participants agreed to four in‐person assessments over 3 weeks
(baseline, and 1, 2, and 3 weeks) and to make daily 5‐minute
phone check‐ins with research staff during the 3‐week period. A
urine sample was also collected at each assessment. All
participants were asked to avoid binge drinking, drug use other
than MJ, and sleep medication for the duration of their study
participation. It was explained that these behaviors would not
affect participation, however, and they should report all drug and
alcohol use accurately on their daily phone diary.
Daily Phone Contact
At baseline, participants chose a 90‐minute window during
which they could make a brief phone call to research staff every
day for the next 3 weeks. They were asked to choose a time as
close to their usual wake time as possible, and to have a diary
ﬁlled out in advance, in order to make the phone call less
burdensome. Participants were given paper copies of the diary,
and completed their ﬁrst diarywith research staff at the baseline
interview.
Statistical Analysis
Weusedmaximum likelihood estimation of generalized linear
mixed effects negative binomial regression models with random
intercepts to model the repeated daily assessment of self‐rated
cognitive impairment and accommodate cases with any missing
assessments. The negative binomial model allows modeling of
the positively skewed count of cognitive impairments symptoms.
All models included planned covariates of: (1) time; (2)
education (Up to High School, Some College); (3) current
employment status (Unemployed, Part‐time, Full‐time); (4)
gender; (5) baseline days of alcohol use; and (6) a term reﬂecting
the main effect of day‐to‐day variation in level of MJ use
(minutes/day). After the main effect of MJ use was evaluated we
added a planned interaction term (MJ use X Gender) to assess
whether the strength of association was different for men
and women. We conducted analysis on the 48 enrolled
participants who provided baseline daily diary phone responses.
All statistical analyseswere completed usingRCoreTeam (2013).
RESULTS
Table 1 lists demographic characteristics of men andwomen
in this study. Daily diary data were available for a mean of
21.86 (SD¼ 3.41) and 21.0 (2.79) of the targeted 22 days for
women and men, respectively. No participants reported use of
sleep medication and seven women (31.8%) and nine men
(34.6%) reported at least one heavy drinking episode during the
assessment period. Average age of ﬁrst MJ use was 15.8 years
of age.
Marijuana Use and Daily Cognitive Difficulty
Marijuana users were separated into the following three
categories: non‐users (n¼ 9), daily MJ users (n¼ 16), and
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non‐daily MJ users (n¼ 23). Non‐users served as the control
group for this sample. On each day ofMJ use, participants were
asked how many minutes they smoked MJ, and during which
hours, the day divided into four 6‐hour quadrants. Daily
smokers were deﬁned as persons smoking MJ at least 6 days/
week, and non‐daily smokers were persons who smoked on at
least 1 day in the past month.
Non‐users were participants who had not smoked MJ in the
last month.
We observed a wide range of MJ use with a median of
10minutes per day for women (Interquartile range¼ 0–50) and
15minutes per day for men (Interquartile range¼ 0–39) during
the 3‐week evaluation period. Our sample also included broad
range of MJ use frequency. Women reported using MJ on a
median of 81% days (Interquartile range, 16–100%) and men
reported using on 86% of observed days (Interquartile range,
18–100%).” A Spearman rank correlation between average
minutes of MJ use during the 3‐week evaluation period and the
percentage of days using MJ during that same period was
rho¼ .88 (p< .001). The correlation between average minutes
use during the 3‐week evaluation period and a baseline DSM‐
IV diagnosis of Cannabis Dependence was r¼ .33 (p¼ .10).
Although not signiﬁcant statistically, those with a diagnosis of
cannabis dependence reported an average of 41.98 (SD
¼ 32.83) minutes as compared to an average of 23.60
(SD¼ 34.36) minutes among those without a diagnosis, a
moderate effect size (Cohen’s d¼ .53).
Levels of daily self‐rated cognitive difﬁculties were a mean
of 3.11 (SD¼ 4.66; Interquartile range¼ 0–5) for women and
1.96 (SD¼ 3.68; Interquartile range¼ 0–2) for men. Evalua-
tion of the main effects in a regression model (see Table 2) with
adjustment for linear effect of time, level of education, current
employment status, gender, baseline days of alcohol use, and
level of MJ use (minutes/day), revealed that there was a
signiﬁcant relationship between greater number of minutes of
MJ use and higher levels of self‐rated cognitive difﬁculties
(b¼ .004; SE¼ .001; p< .006). There was no main effect of
gender (b¼ 1.0; SE¼ .81; p< .22). Planned evaluation of the
interaction between gender and minutes of MJ use was not
signiﬁcant statistically, suggesting a similar relationship
between minutes of MJ use and cognitive difﬁculties among
women compared to men (p< .54).
DISCUSSION
The purpose of this study was to evaluate self‐rated
cognitive ability in males and females using varying levels of
MJ on the same day in a naturalistic setting. Our ﬁndings
support previous studies showing that current and heavier MJ
use affects self‐perceived cognitive ability in both males and
females.
These ﬁndings support numerous studies showing im-
pairment in cognitive ability in humans following MJ use,17
particularly those showing impairments in self‐rated every‐day
memory functioning in MJ users.18 Such impairment may be
related to MJ intoxication, withdrawal, or both. Impairment
may also be related in part to the effect of cannabinoids in
distinct brain areas such as the hippocampus, an area with the
highest density of CB1 receptors that have an important role in
cognition.19 While ﬁndings from previous studies have
focused on low versus high doses of MJ or short versus
long term effects, our study combines these variables in a
naturalistic setting. We found that both men and women
reported problems with cognition on a day‐to‐day basis as a
function of daily time spent smoking MJ.
This study utilized minutes of MJ use as a key predictor
variable. Since there is no accepted standard of measuring MJ
use in the literature, studies have used a wide range of
measurement techniques such as number of joints, blunts,
bowls, puff volume, and duration.20 However, these measure-
ment techniques can be problematic given the variability of THC
content in these methods, and they do not account for different
sizes of joints, for example, or situations in which joints are
shared or not fully smoked. Although varying amounts of THC
can be smoked in similar durations of time, smoking duration
quantiﬁes use in a way related to one of the substance use
disorder criteria (ie, time spent on substance‐related activities).
Therefore, this study may add an additional measure to the
literature that is not subject to existing limitations.
TABLE 2. Results from generalized negative binomial mixed effects models of daily cognitive self‐rating of impairments and minutes of marijuana use
among male and female participants
Variable b SE t‐Value p‐Value
Time (days) .01 .01 1.50 .13
Education 12 .07 .80 .09 .92
Unemployed .88 .75 1.17 .24
Gender: female 1.00 .81 1.24 .22
Baseline days of alcohol use .01 .07 .20 .84
Minutes of marijuana use .004 .001 2.76 .006
Gender X minutes of marijuana usea .002 .003 .61 .54
aTested in separate model. Other parameters reﬂect model with no interaction term.
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This study also used a unique self‐perceived measure of
cognitive ability, a subcategory of the Medical Outcomes
Survey Short‐form. This scale has been widely used with well‐
established validity and reliability.16,21 Use of the cognitive
subscale independently of the larger questionnaire may be a
clinically useful tool. For example, a patient’s self‐perceived
difﬁculty with thinking may be identiﬁed and highlighted by
the clinician as a disadvantage of using MJ.
There were several weaknesses to the current study. First,
sleep quantity or quality was not accounted for in this sample.
This is important as this young adult sample has a high
proportion of sleep problems. An estimated 7.3% of individu-
als aged 18–29 meet ICD‐10 or DSM‐IV criteria for the
diagnosis of insomnia.22 Future studies should analyze sleep
and its inﬂuence on the effects of MJ. Second, tobacco may be
used to compensate for experienced deﬁcits or contribute to
symptoms if nicotine withdrawal symptoms are experienced.
We decided not to include tobacco use as an adjustment in
models assessing relationships between MJ use and cognitive
difﬁculty, and therefore, there may have been a potential effect
of tobacco use on our ﬁndings. Third, we included a limited age
range, and these ﬁndings may not pertain to adolescents or
older adults. Fourth, we did not collect mood measures. Fifth,
while we did have a control group of non‐users who completed
daily assessments of cognition, it is possible that decrements in
self‐rated cognition may have been confounded by the 3‐week
time in the study, that is, even in the absence ofMJ use, the time
in the study may have negatively affected subjective or
objective cognition. Sixth, some participants reported one or
more episodes of heavy drinking during the study, which may
have affected self‐rated cognitive ability. Seventh, this was a
non‐laboratory based study and therefore we do not know ifMJ
use led to deﬁcits in cognition or if deﬁcits in cognition led to
MJ use. This question could be explored in future studies by
reﬁning the assessment to evaluate the temporal relationship
between use and cognitive reporting, or by asking patient to
report their understanding of the temporal relationship (eg,
what came ﬁrst, the MJ use or the difﬁculties with thinking?).
Last, our recruitment strategies focused on “persons 18–29
who drink alcohol or smoke marijuana.” While the sample in
the current study did not report signiﬁcant alcohol use and was
selected to represent primary MJ users, this sample may not be
as reﬂective of a typical MJ using population who typically has
alcohol‐related problems. A recruitment strategy more focused
on MJ only might result in a different population with a greater
proportion of MJ only users. One of the study strengths is that
approximately half of the study participants in this study were
female. Many previous studies on the effect of MJ on cognition
have either not included women23,24 or included fewer women
than men.25–30
When sex differences are examined, the vast majority of
studies show more impairment in females6,31 particularly
heavy MJ using females.6 The explanation for the greater
impact in females is likely multifactorial, including physio-
logical, psychological, and psychosocial differences. Some
have proposed that the increased fatty tissue stored by women
may account for increased storage of THC31,32 and therefore, a
greater impact on functioning. However, women in our study
self‐reported similar impairment at all levels of MJ use
compared to males, suggesting that MJ may affect self‐
reported cognition in females similarly to males. Clinicians
and the public should be informed and research should aim to
understand this. If replicated in a larger sample, this study
suggests that self‐rated cognition declines on the day of MJ
use. For example, it may be that feeling more cognitively
impaired (such as having more ADHD symptoms, doing
poorly on exams or other instances of “intellectual testing”)
may lead to greater MJ use. Whether this could also be
observed in objective testing remains uncertain, but these
ﬁndings reveal important information regarding one conse-
quence of MJ use that has real‐world meaning to young adult
smokers. Whether the use of alcohol and other substances, the
duration (eg, long term use vs. short term use), frequency of
MJ use (eg, daily vs. weekly), and time of assessment relative
to last MJ use inﬂuence cognitive self‐rating is worthy of
further study.
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